GGrantIndex
← Leaderboards

Kenneth P Nephew

Indiana Univ-Purdue Univ At Indianapolis

$7,005,060
Attributed
$7,813,980
Total exposure
8
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $660.5K · FY200525
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$7,813,980 · 8

By mechanism

R01$4,010,450 · 2
P50$1,975,240 · 2
U54$1,640,620 · 1
R29$94,205 · 1
P30$93,465 · 2

Top collaborators

Most similar at Indiana Univ-Purdue Univ At Indianapolis

Same institution · by research overlap

Others in their field

Top investigators on “Tumor

Research focus

TumorMalignant Neoplasm Of OvaryGenesRelapseResistanceChemotherapyDna MethylationResponsePlatinumBaseCellsMalignant NeoplasmsDrug ResistanceEpigenetic ProcessCancer PatientMethylationSamplingBioinformaticsPathway InteractionsSolid NeoplasmDensityCancer TherapyFundingInsight

Grant awards (27)

Linking Epigenetic-Therapy Induction of Inflammasome Signaling to Generation of a BRCAness Phenotype$418,484
P50 · FY2025 · CA · contact PI
Tumor Microenvironment and Metastasis$63,971
P30 · FY2025 · CA · contact PI
Linking Epigenetic-Therapy Induction of Inflammasome Signaling to Generation of a BRCAness Phenotype$401,744
P50 · FY2024 · CA · contact PI
Linking Epigenetic-Therapy Induction of Inflammasome Signaling to Generation of a BRCAness Phenotype$389,189
P50 · FY2023 · CA · contact PI
Tumor Microenvironment and Metastasis Program$29,494
P30 · FY2023 · CA · contact PI
Linking Epigenetic-Therapy Induction of Inflammasome Signaling to Generation of a BRCAness Phenotype$389,189
P50 · FY2022 · CA · contact PI
Linking Epigenetic-Therapy Induction of Inflammasome Signaling to Generation of a BRCAness Phenotype$376,634
P50 · FY2021 · CA · contact PI
An Epigenetic Strategy for Restoring Carboplatin Sensitivity in Ovarian Cancer$323,695
R01 · FY2018 · CA
An Epigenetic Strategy for Restoring Carboplatin Sensitivity in Ovarian Cancer$323,044
R01 · FY2017 · CA
An Epigenetic Strategy for Restoring Carboplatin Sensitivity in Ovarian Cancer$323,701
R01 · FY2016 · CA
An Epigenetic Strategy for Restoring Carboplatin Sensitivity in Ovarian Cancer$323,700
R01 · FY2015 · CA
An Epigenetic Strategy for Restoring Carboplatin Sensitivity in Ovarian Cancer$323,700
R01 · FY2014 · CA
DNA Methylation and Ovarian Cancer$233,953
R01 · FY2012 · CA · contact PI
DNA Methylation and Ovarian Cancer$234,310
R01 · FY2011 · CA · contact PI
DNA Methylation and Ovarian Cancer$241,916
R01 · FY2010 · CA · contact PI
DNA Methylation and Ovarian Cancer$255,015
R01 · FY2009 · CA · contact PI
Predicting Drug Resistance in Cancer Genomes by DMA Methylation Profiling$396,106
U54 · FY2008 · CA · contact PI
DNA Methylation and Ovarian Cancer$264,396
R01 · FY2008 · CA · contact PI
Predicting Drug Resistance in Cancer Genomes by DMA Methylation Profiling$433,347
U54 · FY2007 · CA · contact PI
Predicting Drug Resistance in Cancer Genomes by DMA Methylation Profiling$276,377
U54 · FY2006 · CA · contact PI
Predicting Drug Resistance in Cancer Genomes by DMA Methylation Profiling$268,329
U54 · FY2005 · CA
DNA Methylation and Ovarian Cancer$265,220
R01 · FY2005 · CA
DNA Methylation and Ovarian Cancer$294,457
R01 · FY2004 · CA
Predicting Drug Resistance in Cancer Genomes by DMA Methylation Profiling$266,461
U54 · FY2004 · CA
DNA Methylation and Ovarian Cancer$295,328
R01 · FY2003 · CA
DNA Methylation and Ovarian Cancer$308,015
R01 · FY2002 · CA
TAMOXIFEN AND RETINOIC ACID EFFECT ON THE UTERUS$94,205
R29 · FY2000 · CA